Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer

被引：0
作者：
Urun, Yonca Yilmaz [1 ]
Beypinar, Ismail [2 ]
机构：
[1] Van Yuzuncuyil Univ, Dept Gastroenterol, Van, Turkiye
[2] Alanya Alaaddin Keykubat Univ, Dept Med Oncol, Alanya, Turkiye
来源：
MEDICAL SCIENCE MONITOR | 2025年 / 31卷
关键词：
Blood Cell Count; Esophagus; Inflammation; Prognosis; SQUAMOUS-CELL CARCINOMA; TO-LYMPHOCYTE RATIO; EPIDEMIOLOGY; SURVIVAL;
D O I：
10.12659/MSM.947202
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background: Globally, esophageal cancer ranks as the sixth leading cause of cancer-related mortality. This retrospective study from a single center in Turkey aimed to evaluate hematological inflammatory biomarkers in complete blood count (CBC) data and outcomes in 113 patients with advanced esophageal carcinomas. Material/Methods: We conducted a retrospective analysis of 113 patients with metastatic esophageal cancer composed of squamous (92), adenocarcinoma (18), and small cell (3) histology. We investigated neutrophil-to-lymphocyte ratio tory response index (SIRI), and aggregate index of systemic inflammation (AISI) in terms of prognosis. Results: The initial treatment for 25.7% of patients consisted of a carboplatin-paclitaxel combination. In response to the initial round of chemotherapy, 52.2% of patients showed improvement (15% complete, 37.2% partial), while 18.6% experienced disease progression. Neutropenia was observed as the most prevalent severe (grades 3-4) adverse reaction, affecting 19.8% of patients. Higher NLR, PLR, SII, NLPR, SIRI, and AISI values were associated with worse survival (P=0.016, P=0.008, P=0.011, P=0.028, P=0.014, P=0.001, respectively), whereas higher LMR was correlated with better survival (P=0.001). The NMR analysis showed no significant association (P=0.46). Multivariate analysis identified independent prognostic factors except histology, PLR, and NLPR. Conclusions: Research indicates that inflammatory indicators obtained from complete blood count analyses possess prognostic significance for individuals with metastatic esophageal cancer. These biomarkers demonstrate diverse capacities in forecasting the course of the disease. These simple and inexpensive markers need further confirmation to guide individualized treatment planning.
引用
收藏
页数：9
相关论文
共 41 条
  • [1] Sung H, Ferlay J, Siegel RL, Et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Cancer J Clin, 71, 3, pp. 209-249, (2021)
  • [2] Morgan E, Soerjomataram I, Rumgay H, Et al., The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020, Gastroenterology, 163, 3, pp. 649-658, (2022)
  • [3] Siegel RL, Giaquinto AN, Jemal A., Cancer statistics, 2024, Cancer J Clin, 74, 1, pp. 12-49, (2024)
  • [4] Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I., Global burden of oesophageal and gastric cancer by histology and subsite in 2018, Gut, 69, 9, pp. 1564-1571, (2020)
  • [5] Chen Z, Ren Y, Du XL, Et al., Incidence and survival differences in esophageal cancer among ethnic groups in the United States, Oncotarget, 8, 29, pp. 47037-47051, (2017)
  • [6] Siegel RL, Miller KD, Jemal A., Cancer statistics, 2019, Cancer J Clin, 69, 1, pp. 7-34, (2019)
  • [7] Smyth EC, Lagergren J, Fitzgerald RC, Et al., Oesophageal cancer, Nat Rev Dis Primer, 3, (2017)
  • [8] Patel N, Benipal B., Incidence of esophageal cancer in the United States from 2001-2015: A United States cancer statistics analysis of 50 states, Cureus, 10, 12, (2018)
  • [9] Napier KJ, Scheerer M, Misra S., Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities, World J Gastrointest Oncol, 6, 5, pp. 112-120, (2014)
  • [10] Liang H, Fan JH, Qiao YL., Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China, Cancer Biol Med, 14, 1, pp. 33-41, (2017)
12345